ID: ALA5278736

Max Phase: Preclinical

Molecular Formula: C29H30N4O10

Molecular Weight: 594.58

Representations

Canonical SMILES:  NC[C@H]1O[C@@H](O[C@@H](C#Cc2ccc(NC(=O)c3ccccc3)cc2)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C29H30N4O10/c30-14-19-21(35)24(38)28(42-19)41-18(25-22(36)23(37)27(43-25)33-13-12-20(34)32-29(33)40)11-8-15-6-9-17(10-7-15)31-26(39)16-4-2-1-3-5-16/h1-7,9-10,12-13,18-19,21-25,27-28,35-38H,14,30H2,(H,31,39)(H,32,34,40)/t18-,19+,21+,22-,23+,24+,25+,27+,28+/m0/s1

Standard InChI Key:  DRMVAROTPYELMZ-GUUNXTRESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 594.58

Molecular Weight (Monoisotopic): 594.1962

AlogP: -1.75

#Rotatable Bonds: 7

Polar Surface Area: 218.59

Molecular Species: BASE

HBA: 12

HBD: 7

#RO5 Violations: 3

HBA (Lipinski): 14

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.70

CX Basic pKa: 8.75

CX LogP: -0.60

CX LogD: -1.72

Aromatic Rings: 3

Heavy Atoms: 43

QED Weighted: 0.15

Np Likeness Score: 0.43

References

1. Okamoto K, Ishikawa A, Okawa R, Yamamoto K, Sato T, Yokota SI, Chiba K, Ichikawa S..  (2021)  Design, synthesis and biological evaluation of simplified analogues of MraY inhibitory natural product with rigid scaffold.,  55  [PMID:35016115] [10.1016/j.bmc.2021.116556]

Source

Source(1):

• Scientific Literature